Viatris shares rise 5.04% intraday after appointing Matthew Maletta as Chief Legal Officer with extensive industry experience.

Viatris surged 5.04% intraday following the announcement of Matthew J. Maletta's appointment as Chief Legal Officer, effective February 9, 2026. The transition of long-serving CLO Brian Roman, who will remain through April 2026, was accompanied by positive commentary from CEO Scott A. Smith, emphasizing Maletta’s 30-year legal expertise in pharmaceutical mergers and business development, including his role in Allergan’s $70 billion sale to Actavis. The news reinforced investor confidence in Viatris.